Crovalimab Emerging Drug Insight

“Crovalimab Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Crovalimab for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) in the 7MM. A detailed picture of the Crovalimab in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Crovalimab. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Crovalimab market forecast, analysis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies.

Drug Summary

Crovalimab (RG6107, SKY59) is a humanized complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of several diseases. As the complement system is a key innate immune defense mechanism, the company plans to study the potential of this antibody in a broader range of complement-mediated diseases.

Crovalimab is a novel anti-C5 humanized monoclonal antibody (mAb) developed by the Hoffmann La Roche pharmaceutical company; however, Chugai Pharmaceuticals, a Japanese company, created it. It is described as a sequential mAb recycling technology for extended self-administered subcutaneous doses for C5 inhibition. This drug is engineered with Sequential Monoclonal Antibody Recycling Technology (SMART) that improves the drug’s half-life and facilitates subcutaneous dosing while still achieving complete C5 inhibition C5 inhibition.

Crovalimab binds to the C5 β-chain and prevents cleavage of the wild-type and SNP C5 by the C5 convertase. In addition, it uniquely inhibits C5b6 deposition on membranes, further limiting membrane attack complex-mediated tissue damage. SMART has led to limited C5 accumulation and increased C5 binding capacity in nonhuman primates.

Currently, the drug is in Phase III clinical development for the treatment of aHUS. It is being investigated in two Phase III clinical trials starting in October and November 2021. Both of these trials are a Phase III, multicenter, single-arm study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of Crovalimab in adult and adolescent patients with aHUS and are expected to be completed by March 2024 and December 2025 respectively.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Crovalimab description, mechanism of action, dosage and administration, research and development activities in Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH).
• Elaborated details on Crovalimab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Crovalimab research and development activity in Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Crovalimab.
• The report contains forecasted sales of Crovalimab for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH).
• The report also features the SWOT analysis with analyst views for Crovalimab in Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Crovalimab Analytical Perspective by DelveInsight

• In-depth Crovalimab Market Assessment

This report provides a detailed market assessment of Crovalimab in Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Crovalimab Clinical Assessment

The report provides the clinical trials information of Crovalimab for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Crovalimab dominance.
• Other emerging products for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) are expected to give tough market competition to Crovalimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Crovalimab in Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH).
• Our in-depth analysis of the forecasted sales data of Crovalimab from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Crovalimab in Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH).

Key Questions

• What is the product type, route of administration and mechanism of action of Crovalimab?
• What is the clinical trial status of the study related to Crovalimab in Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Crovalimab development?
• What are the key designations that have been granted to Crovalimab for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH)?
• What is the forecasted market scenario of Crovalimab for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH)?
• What are the forecasted sales of Crovalimab in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH) and how are they giving competition to Crovalimab for Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH)?
• Which are the late-stage emerging therapies under development for the treatment of Atypical Hemolytic Uremic Syndrome and paroxysmal nocturnal hemoglobinuria (PNH)?